Additionally, combination therapy with TIMELESS depletion and either Wee1 or CHK1 inhibition demonstrated at least additive effects in four colon cancer cell lines, but not in HCECs (Fig 6), suggesting this combination may be an efficacious strategy for the treatment of colon cancer. The gene discussed is CHEK1; the disease is malignant colon neoplasm.